T807 AV-1451|cas:1415379-56-4|西域试剂

T807 AV-1451,99.06%

产品编号：Bellancom-101184| CAS NO：1415379-56-4| 分子式：C₁₆H₁₀FN₃| 分子量：263.27

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101184	￥800.00	杭州北京（现货）
Bellancom-101184	￥1350.00	杭州北京（现货）
Bellancom-101184	￥4100.00	杭州北京（现货）
Bellancom-101184	￥7000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

T807 AV-1451

产品介绍

T807是一种新型的tau正电子发射断层扫描 (PET) 示踪剂。

生物活性

T807 a novel tau positron emission tomography (PET) tracer.

体外研究

Aggregated tau protein is a major neuropathological substrate central to the pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD). In vitro autoradiography results show that [¹⁸F]T807 exhibits strong binding to PHF-tau positive human brain sections (K_d=14.6 nM). A comparison of autoradiography and double immunohistochemical staining of PHF-tau and Ab on adjacent sections demonstrates that [¹⁸F]T807 binding colocalizes with immunoreactive PHF-tau pathology, but does not highlight Ab plaques. [¹⁸F]T807 strongly binds to tau lesions primarily made of paired helical filaments in Alzheimer’s brains e.g. intra and extraneuronal tangles and dystrophic neurites. [¹⁸F]T807 off-target binding to neuromelanin- and melanin-containing cells and, to a lesser extent, to brain hemorrhagic lesions is identified.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

[¹⁸F]T807 is able to cross the blood–brain barrier and ished out quickly in mice model. [¹⁸F]T807 clears rapidly from the brain, with activity values decreasing from 4.43% ID/g at 5 minutes to 0.62% ID/g at 30 minutes. Kidney elimination is a significant clearance pathway, resulting in a maximum tracer concentration of 14.99% ID/g in the kidneys at 5 minutes, which decreases to 5.52% ID/g at 30 minutes. The accumulation of activity in muscle and bone remain relatively low throughout the PET scan.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 16.6 mg/mL (63.05 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7984 mL	18.9919 mL	37.9838 mL
5 mM	0.7597 mL	3.7984 mL	7.5968 mL
10 mM	0.3798 mL	1.8992 mL	3.7984 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1.25 mg/mL (4.75 mM); Suspended solution; Need ultrasonic

此方案可获得 1.25 mg/mL (4.75 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.25 mg/mL (4.75 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (4.75 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。